0001104659-26-034911
SEC filingMetaVia Inc. reported a net loss of $13.0 million for fiscal year 2025, a significant improvement from a net loss of $27.6 million in 2024, representing a 53.0% reduction. This improvement was driven by a 52.4% decrease in total operating expenses to $13.7 million, primarily due to a 68.4% reduction in research and development expenses to $6.8 million. The company generated no revenue and recorded a loss from operations of $13.7 million. Cash and cash equivalents stood at $10.3 million as of December 31, 2025, with an accumulated deficit of $148.8 million. Management has expressed substantial doubt about the company's ability to continue as a going concern within one year, citing ongoing net losses and negative cash flows from operating activities of $15.7 million in 2025.
MetaVia Inc. reported a net loss of $13.0 million for fiscal year 2025, representing a significant improvement from the $27.6 million net loss in 2024. Total operating expenses decreased by 52.4% to $13.7 million, primarily driven by a 68.4% reduction in research and development expenses to $6.8 million. General and administrative expenses also decreased by 4.8% to $6.9 million. The company recorded a loss from operations of $13.7 million, identical to total operating expenses since no revenue was generated. Other income totaled $0.7 million, consisting of a $0.2 million gain from change in fair value of warrant liabilities and $0.5 million in net interest income. Basic and diluted loss per share was $7.35, compared to $39.13 in the prior year, with weighted average shares outstanding of 1.8 million.
The company generated no revenue during fiscal year 2025, consistent with its history as a clinical-stage biotechnology company. MetaVia has not generated any revenue from product sales, collaborations, government grants, or other sources since inception. The company's operations consist principally of research and development activities, including preclinical development and clinical trials for its product candidates vanoglipel (DA-1241) and DA-1726. Management does not expect to generate significant revenue unless and until marketing approval is obtained for one or more product candidates, and there is no certainty that such approval will be achieved.
As a pre-revenue company, MetaVia reported negative operating and net income margins. The company's cost structure showed significant improvement in 2025, with total operating expenses decreasing by $15.1 million compared to 2024. Research and development expenses decreased by $14.8 million to $6.8 million, primarily due to decreased activities related to Phase 2a clinical trials for vanoglipel and Phase 1 clinical trials for DA-1726. General and administrative expenses decreased by $0.4 million to $6.9 million, primarily due to lower consulting expenditures and insurance costs. The company recorded no provision for income taxes due to a full valuation allowance on deferred tax assets.
MetaVia used $15.7 million in cash for operating activities during 2025, primarily due to the net loss of $13.0 million adjusted for non-cash items including $0.4 million in stock-based compensation and $0.2 million in depreciation. Changes in operating assets and liabilities included a $2.8 million decrease in accounts payable and a $0.5 million increase in prepaid expenses. Investing activities used $2,000 for purchases of property and equipment. Financing activities provided $10.0 million from the issuance of common stock and warrants under private placement offerings. As of December 31, 2025, the company had $10.3 million in cash and cash equivalents, total assets of $11.1 million, total liabilities of $5.8 million, and stockholders' equity of $5.3 million with an accumulated deficit of $148.8 million.
Management has expressed substantial doubt about MetaVia's ability to continue as a going concern within one year from the issuance of the financial statements. The company expects to continue incurring net losses and negative cash flows from operating activities for the foreseeable future as it advances product candidates through clinical development. MetaVia anticipates increasing R&D expenses for additional planned clinical trials and will require additional capital to accomplish its business plan. The company is exploring financing opportunities but has no commitments for additional financing. Key strategic priorities include advancing clinical development for vanoglipel and DA-1726, maintaining intellectual property protection, and potentially establishing commercialization capabilities if regulatory approvals are obtained. Risk factors include the uncertainty of clinical trial outcomes, regulatory approvals, and the company's ability to secure necessary funding.